Inhibrx Biosciences (INBX) Revenue (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Revenue data on file, last reported at $1.3 million in Q2 2025.

• On a quarterly basis, Revenue rose 1200.0% year-over-year to $1.3 million in Q2 2025; TTM through Dec 2025 was $1.4 million, a 23.66% decrease from a year earlier, with the FY2025 full-year figure at $1.3 million, up 550.0% from the prior year.
• Revenue for Q2 2025 stood at $1.3 million, up from $100000.0 in the prior quarter.
• Over the last five years, Revenue for INBX reached as high as $1.6 million in Q4 2023 and fell as low as $30000.0 in Q2 2023.
• Historically, Revenue has averaged $547166.7 across 3 years, with a median of $109500.0 in 2023.
• Across the five-year window, Revenue tumbled 93.88% in 2024 and soared 1200.0% in 2025, its largest moves.
• Year by year, Revenue stood at $1.6 million in 2023, then tumbled by 93.88% to $100000.0 in 2024, then surged by 1200.0% to $1.3 million in 2025.
• Per Business Quant data, the three most recent Revenue figures were $1.3 million in Q2 2025, $100000.0 in Q4 2024, and $100000.0 in Q2 2024.